hereby acrtify that this correspondence is being deposited with the United States Posite Sprains with the Un

Attorney Docket No.: 018148-

Assistant Commissioner for Patents Washington, D.C. 20231

on December 4, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Sylva & arnold

DEC 1 1 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner:

Tu, Stephen

DAVID S. DIME et al.

Art Unit:

1653

Application No.: 09/367,794

AMENDMENT

Filed: August 19, 1999

For: SITE-SPECIFIC DRUG

DELIVERY

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

In response to the Office Action mailed April 23, 2002, please amend the aboveidentified application as follows. A petition for a 3-month extension of time is being filed concurrently herewith.

IN THE SPECIFICATION:

Please replace the paragraph at page 16, lines 14-20 of the specification, with the following amended paragraph:

-- Many drugs that modify protein function bind with dissociation constants of about 100 nM to 10 μM. Optimally, the anchoring groups bind the chosen unique domains with about 100-fold higher affinity than the drugs bind to their targets. Therefore, the binding affinity of the anchoring groups will control localization or binding of the drug to the target protein and